Safety of anti-tumor necrosis factor agents in psoriatic arthritis – an update

Abstract

Introduction: Tumor necrosis factor (TNF) blockers have represented a real revolution in the treatment of rheumatoid arthritis and spondyloarthritides (SpAs). In the case of psoriatic arthritis (PsA), anti-TNF agents are much more effective than conventional disease modifying antirheumatic drugs on all manifestations of the disease, that is, axial involvement, peripheral arthritis, peripheral enthesitis, dactylitis and skin lesions. A complete understanding of their safety is fundamental in clinical practice.

Areas covered: This article addresses the safety of anti-TNF therapy in PsA. A systematic literature review was performed using the largest electronic databases (MEDLINE, EMBASE and COCHRANE). The reported data were derived from randomized controlled trials, open-observational studies and meta-analyses. Useful information derived from the experiences in rheumatoid arthritis has also been reported.

Expert opinion: Anti-TNF therapies are as safe as conventional disease-modifying antirheumatic drugs in the management of psoriatic arthritis when the candidate patients are accurately selected. An adverse event could still occur when the patient is managed according to current national and/or international recommendations; therefore, tight controls aimed to detect adverse events early is mandatory.

Keywords::

• adalimumab
• adverse event
• anti-TNF
• etanercept
• golimumab
• infliximab
• psoriatic arthritis
• safety

Declaration of interests

The authors have received honoraria from Abbvie, BMS, MSD, Pfizer, Roche, and UCB to attend scientific meetings. The authors have received no payment in preparation of this manuscript.

Notes

This box summarizes key points contained in the article.